科研之友
微信
新浪微博
Facebook
分享链接
摘要
Purpose: Chemotherapy represents one of the major treatments for non-small-cell lung cancer (NSCLC), while its drug resistance and high toxicity raise big concerns. Astragalus-based Chinese traditional patent medicine combined with chemotherapy was frequently used for treatment of NSCLC in China. However, its effectiveness hasn't been systematically analyzed. The present study aimed to evaluate the benefits of Astragalus-based Chinese traditional patent medicine combined with chemotherapy for NSCLC. Methods: The randomized controlled trials involving NSCLC treatment with Astragalus-based Chinese traditional patent medicine combined with chemotherapy were screened. The Review Manager 5.3 software was employed for data analysis. Funnel plot were applied to evaluate publication bias. Results: 15 eligible studies met our criteria. 15 studies indicated increase tumor response. 8, 6, and 4 studies revealed reduced toxicity including leucopenia, thrombopenia, nausea and vomiting, respectively. Conclusion: Astragalus-based Chinese traditional patent medicine may benefit the treatment of NSCLC through increasing effectiveness and reducing the toxicity of chemotherapy. More full-scale randomized clinical trials and long-term effectiveness are recommended to further evaluate for treatment of NSCLC.
